Related Experiment Video
Updated: Aug 7, 2026
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
Statin Use and the Risk of Proliferative Vitreoretinopathy in Eyes Undergoing Rhegmatogenous Retinal Detachment
Sidra Zafar1, Nitika Aggarwal2, Sudheshna Vemula1
1Mid Atlantic Retina, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Background And Objective:
This study aimed to evaluate the association between statin use and frequency of proliferative vitreoretinopathy (PVR) and return to the operating room in eyes undergoing rhegmatogenous retinal detachment (RRD) repair.
Patients And Methods:
This was a retrospective study of all patients ≥18 years of age who underwent RRD repair between January 2015 and November 2024, identified in the Vestrum Health Retina Database.
Results:
A total of 54,876 eyes were included in the final analysis, of which 17,922 (33%) were taking statins. The frequency of PVR development within 90 days following primary RRD repair was significantly lower in the statin group compared to the non-statin group (6.67% vs. 8.17%, P < .001). In a multivariate regression analysis adjusted for age, sex, smoking history, lens status, diabetes, and surgery type, statin use was independently associated with a decreased likelihood of PVR (odds ratio: 0.70, 95% CI: 0.66 to 0.75).
Conclusion:
Statin use was associated with a significantly lower risk for PVR formation and return to the operating room following primary RRD repair.
